SXTP
NASDAQ · Pharmaceuticals
60 Degrees Pharma Inc
$1.16
+0.12 (+11.54%)
Financial Highlights (FY 2026)
Revenue
7.39M
Net Income
-38,649,230
Gross Margin
44.5%
Profit Margin
-522.7%
Rev Growth
+40.2%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 44.5% | 44.5% | 46.3% | 46.3% |
| Operating Margin | -550.6% | -495.5% | 30.7% | 30.1% |
| Profit Margin | -522.7% | -496.6% | 23.1% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.39M | 5.27M | 862.6K | 990.0K |
| Gross Profit | 3.29M | 2.35M | 399.5K | 458.5K |
| Operating Income | -40,713,929 | -26,134,039 | 264.9K | 298.0K |
| Net Income | -38,649,230 | -24,808,720 | 198.9K | 215.4K |
| Gross Margin | 44.5% | 44.5% | 46.3% | 46.3% |
| Operating Margin | -550.6% | -495.5% | 30.7% | 30.1% |
| Profit Margin | -522.7% | -496.6% | 23.1% | 21.8% |
| Rev Growth | +40.2% | +40.2% | -6.7% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 71.0K | 71.0K | 1.77M | 1.68M |
| Total Equity | 1.61M | 1.61M | 3.39M | 2.90M |
| D/E Ratio | 0.04 | 0.04 | 0.52 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -40,486,504 | -27,431,837 | 334.7K | 417.4K |
| Free Cash Flow | — | — | 224.8K | 208.8K |